ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2,1,Bacterial sepsis,Bacterial infections NEC,Bacterial infectious disorders,Infec,Y
2,2,Fungaemia,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
3,1,Pathogen resistance,Infections NEC,Infections - pathogen unspecified,Infec,N
3,2,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
4,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4,2,Pathogen resistance,Infections NEC,Infections - pathogen unspecified,Infec,N
4,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
5,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
6,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
6,2,Blood albumin decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
6,3,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
7,1,Critical illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
7,2,Minimum inhibitory concentration increased,Microbiology and serology tests NEC,Microbiology and serology investigations,Inv,N
7,3,Renal tubular acidosis,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
8,1,Hypernatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
8,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
8,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
9,1,Hypernatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
9,2,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
10,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
10,2,Hypernatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
10,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
11,1,Hypernatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
11,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,Y
11,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
12,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
12,2,Hypernatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
12,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
13,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
14,1,Insulin-like growth factor decreased,Endocrine analyses and imaging NEC,Endocrine investigations (incl sex hormones),Inv,N
14,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
15,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
15,2,Pathogen resistance,Infections NEC,Infections - pathogen unspecified,Infec,N
16,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
17,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
17,2,Incorrect drug administration rate,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
17,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
17,4,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
17,5,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
18,1,Cystitis klebsiella,Klebsiella infections,Bacterial infectious disorders,Infec,N
18,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
19,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
19,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
19,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
19,4,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
20,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
20,2,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
20,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
21,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
21,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
21,3,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
21,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
21,5,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
21,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
22,1,Cytomegalovirus infection reactivation,Cytomegaloviral infections,Viral infectious disorders,Infec,N
23,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
23,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
23,3,Product administered to patient of inappropriate age,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
24,1,Drug reaction with eosinophilia and systemic symptoms,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
24,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
24,3,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
25,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
26,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
27,1,Osteomyelitis,Bone and joint infections,Infections - pathogen unspecified,Infec,N
27,2,Pathogen resistance,Infections NEC,Infections - pathogen unspecified,Infec,N
28,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
28,2,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
28,3,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
28,4,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
28,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
28,6,Pancreatitis acute,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,Y
28,7,Pulseless electrical activity,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
29,1,Enterobacter bacteraemia,Enterobacter infections,Bacterial infectious disorders,Infec,N
29,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
29,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
29,4,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
30,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
31,1,Hypernatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
32,1,Drug eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
33,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
34,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
35,1,Multiple-drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
36,1,Multiple-drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
37,1,Multiple-drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
38,1,Multiple-drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
39,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
